Dipanjan Pan is an Indian American academic who is the Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at Pennsylvania State University.[1]

Dipanjan Pan
NationalityAmerican
Occupation(s)Academic
Entrepreneur
Academic background
Alma materIndian Institute of Technology
Academic advisorsKaren L. Wooley
Academic work
InstitutionsWashington University in St. Louis

University of Illinois at Urbana-Champaign
University of Maryland Baltimore School of Medicine
University of Maryland Baltimore County

Pennsylvania State University

Early life and education edit

Dipanjan Pan was born in India.[2] He obtained his doctoral degree from the Indian Institute of Technology and subsequently joined Washington University in St. Louis.[3] There, he collaborated with Karen L. Wooley on investigating the utilization of self-assembled polymeric nanoparticles for targeted drug delivery applications.[3]

Career edit

Pan started his career in 2005 as an intellectual property analyst in chemistry at General Electric's John F. Welch Technology Centre.[4]

In 2007, he joined the Washington University School of Medicine in Saint Louis as a research instructor.[4][5] In 2010, he became an assistant professor in medicine and served until 2013, contributing to the field of cardiovascular research.[4][6]

In 2013, Pan joined the University of Illinois Urbana-Champaign as an assistant professor.[4]

In 2014, Pan co-founded InnSight Technology, a preclinical company, along with Leanne Labriola.[7] Two years later, in 2016, he co-founded KaloCyte, a company that has developed an artificial blood called Erythromer, with Allan Doctor and Philip Spinella.[8][9] He has served as a professor of radiology in the school of medicine, and professor of chemical and biochemical and environmental engineering at the University of Maryland, Baltimore County.[10][11]

Pan is the current head of the Pan Laboratory for Materials in Medicine.[12]

Research edit

His research focuses on the development and application of nanoscale materials and techniques for the diagnosis and treatment of various diseases, particularly cancer and cardiovascular disorders.[3]

In 2014, Pan and his team reported a novel method for inhibiting cancer cell growth using nanotechnology, as detailed in a paper presented at the American Chemical Society conference.[13] The preliminary research demonstrated success in impeding breast cancer and melanoma cell growth in laboratory settings by delivering a synthetic compound mimicking venom from bees, snakes, and scorpions.[13][14]

In 2015, Pan, Leanne Labriola, and other team members developed a portable sensor named OcuCheck that assesses ocular injuries through the quantification of vitamin C concentration in a patient's tears at the University of Illinois.[15]

In 2018, Pan and other researchers at the University of Illinois created a gel utilizing gold nanoparticles which has the capability to rapidly detect ocular trauma.[16]

In 2020, Pan and his team initiated the development of rapid tests for detecting COVID-19.[17][18] Within six months, they created their first test, followed by four more by the end of 2021.[19] Three tests, including the Antisense test, have been licensed for commercialization and registered with the Food and Drug Administration.[19] Later, he founded a company called VitruVian Bio to further develop the test for commercial applications.[20][21]

In 2023, Dipanjan Pan and his research team developed the first rapid test for monkeypox, as reported in the journal Advanced Functional Materials.[22] It uses a selective molecular sensor that can detect the virus within minutes.[22] The method employs nanomaterial heterostructures, consisting of zero-dimensional spherical gold nanoparticles and two-dimensional hafnium disulfide nanoplatelets, as building blocks to create a platform technology capable of detecting trace amounts of genetic material in biological samples.[22]

Awards and recognition edit

  • 2014: Elected Fellow of the Royal Society of Chemistry[4]
  • 2016: Nanomaterials Letter Researcher Award[4]
  • 2016: Elected Fellow of AHA[23]
  • 2018: Elected Fellow of ACC[24]
  • 2018: Dean's Award[25]
  • 2020: COVID-19 Hero Award[26]
  • 2021: Maryland Industrial Partnerships (MIPS) Award[27]
  • 2023: Elected Fellow of AIMBE[28]

Bibliography edit

  • Nanomedicine: A Soft Matter Perspective
  • Personalized Medicine with a Nanochemistry Twist: Nanomedicine

References edit

  1. ^ "Dipanjan Pan". 11 July 2022.
  2. ^ "Indian-Origins Among Researchers to Develop Portable Sensor to Quickly Detect Severe Eye Injury".
  3. ^ a b c "Professor Dipanjan Pan, PHD, FRSC, FAHA, FACC | - the Pan Research Group".
  4. ^ a b c d e f "Professor Dipanjan Pan".
  5. ^ "Pastries-like nanoparticles may help fight".
  6. ^ "Nanoparticles Can Detect Blood Clots".
  7. ^ "Tale of a teardrop: Pine eye specialist developing device that could signal disease".
  8. ^ "UMSOM bringing artificial blood product one step closer to reality | Maryland Daily Record". 6 February 2023.
  9. ^ "University of Maryland School of Medicine physician-scientist to lead high-budget research project to develop artificial blood".
  10. ^ "St. Louis biotech company moves to Baltimore to develop fake blood for real emergencies". Baltimore Sun.
  11. ^ "Rapid COVID-19 tests now available in some Maryland doctors' offices but questions about accuracy persist". Baltimore Sun.
  12. ^ Staff, Daily Record (June 23, 2022). "DIPANJAN PAN | Maryland Daily Record".
  13. ^ a b "Bee, scorpion and snake venom may hold cancer cure". CNN. 12 August 2014.
  14. ^ "Live Well: How to avoid 'brain freeze' from cold drinks and bee venom could help fight cancer".
  15. ^ "Vitamin C-detecting sensor could assess eye injuries on the spot". 10 December 2015.
  16. ^ "Color-changing sensor detects signs of eye damage in tears".
  17. ^ "Paper-based electrochemical sensor can detect COVID-19 in less than five minutes".
  18. ^ "Researchers develop experimental rapid COVID-19 test using nanoparticle technique".
  19. ^ a b "DIPANJAN PAN | Maryland Daily Record". 23 June 2022.
  20. ^ "Researchers develop experimental rapid COVID-19 test using nanoparticle technique: Advanced nanotechnology provides 'naked eye' visual detection of virus in 10 minutes".
  21. ^ "UMBC's Dipanjan Pan Develops Rapid Diagnostic Test for Virus Causing COVID-19 - UMBC: University of Maryland, Baltimore County". 9 June 2020.
  22. ^ a b c "First rapid test for mpox developed, tech adaptable for other emerging diseases | Penn State University". www.psu.edu.
  23. ^ "Fellow of the American Heart Association". University of Illinois Urbana-Champaign.
  24. ^ Communications, Grainger Engineering Office of Marketing and. "Pan elected Fellow of American College of Cardiology". bioengineering.illinois.edu.
  25. ^ Communications, Grainger Engineering Office of Marketing and. "Dipanjan Pan earns outstanding college of engineering research honor". bioengineering.illinois.edu.
  26. ^ Staff, Daily Record (June 23, 2022). "DIPANJAN PAN | Maryland Daily Record".
  27. ^ "UMBC Faculty, Alumni Entrepreneurs Receive Record Number Of MIPS Awards For Tech Collaborations - UMBC: University Of Maryland, Baltimore County". February 11, 2021.
  28. ^ "AIMBE" (PDF).